Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. The new drugs used for treating AML are facing a big challenge, and the candidates include cytotoxic drugs, targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Min, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933364/
https://www.ncbi.nlm.nih.gov/pubmed/29750014
http://dx.doi.org/10.2147/DDDT.S161199
_version_ 1783319957108424704
author Lin, Min
Chen, Baoan
author_facet Lin, Min
Chen, Baoan
author_sort Lin, Min
collection PubMed
description Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. The new drugs used for treating AML are facing a big challenge, and the candidates include cytotoxic drugs, targeted small-molecule inhibitors, and monoclonal antibodies. In recent years, active research has focused on several new agents for including them in the large antileukemic drug family. This review aims to introduce some of these new drugs and highlights new advances made in the old drugs, mainly in the last 5 years.
format Online
Article
Text
id pubmed-5933364
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59333642018-05-10 Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia) Lin, Min Chen, Baoan Drug Des Devel Ther Review Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. The new drugs used for treating AML are facing a big challenge, and the candidates include cytotoxic drugs, targeted small-molecule inhibitors, and monoclonal antibodies. In recent years, active research has focused on several new agents for including them in the large antileukemic drug family. This review aims to introduce some of these new drugs and highlights new advances made in the old drugs, mainly in the last 5 years. Dove Medical Press 2018-04-30 /pmc/articles/PMC5933364/ /pubmed/29750014 http://dx.doi.org/10.2147/DDDT.S161199 Text en © 2018 Lin and Chen. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Lin, Min
Chen, Baoan
Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
title Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
title_full Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
title_fullStr Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
title_full_unstemmed Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
title_short Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
title_sort advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933364/
https://www.ncbi.nlm.nih.gov/pubmed/29750014
http://dx.doi.org/10.2147/DDDT.S161199
work_keys_str_mv AT linmin advancesinthedrugtherapiesofacutemyeloidleukemiaexceptacutewpromyelocyticleukemia
AT chenbaoan advancesinthedrugtherapiesofacutemyeloidleukemiaexceptacutewpromyelocyticleukemia

Ejemplares similares